Therapeutic potentials of *Crataegus azarolus* var. *eu-azarolus* Maire leaves and its isolated compounds

Eman Abu-Gharbieh¹,²* and Naglaa Gamil Shehab³

**Abstract**

**Background:** Hyperglycemia is a complicated condition accompanied with high incidence of infection and dyslipidemia. This study aimed to explore the phyto-constituents of *Crataegus azarolus* var. *eu-azarolus* Maire leaves, and to evaluate the therapeutic potentials particularly antimicrobial, antihyperglycemic and antihyperlipidemic of the extract and the isolated compound (3β-O-acetyl ursolic acid).

**Methods:** Total phenolics and flavonoidal contents were measured by RP-HPLC analysis. Free radicals scavenging activity of different extraction solvents was tested in-vitro on DPPH free radicals. The antimicrobial activity of the ethanolic extract and its fractions as well as the isolated compounds were evaluated in-vitro on variable microorganisms. Animal models were used to evaluate the antihyperglycemic and antihyperlipidemic activities of the ethanolic extract along with the isolated compound (3β-O acetyl ursolic acid).

**Results:** RP-HPLC analysis of the phenolics revealed high content of rutin, salicylic and ellagic acids. Six compounds belonging to triterpenes and phenolics were isolated from chloroform and *n*-butanol fractions namely: ursolic acid, 3β-O-acetyl ursolic acid, ellagic acid, quercetin 3-O-β methyl ether, rutin and apigenin7-O-rutinoside. Ethanolic extract showed the highest DPPH radical scavenger activity compared to other solvents. Ethanolic extract, hexane fraction, ursolic acid, 3β-O acetyl ursolic acid and quercetin 3-O-methyl ether showed variable antimicrobial activity against *E. coli*, *P. aeruginosa*, *S. aureus*, and *C. albicans*. Administration of the ethanolic extract or 3β-O acetyl ursolic acid orally to the mice reduced blood glucose significantly in a time- and dose-dependent manner. Ethanolic extract significantly reduced LDL-C, VLDL-C, TC and TG and increased HDL-C in rats. Ethanolic extract and 3β-O acetyl ursolic acid reduced in-vitro activity of pancreatic lipase.

**Conclusion:** This study reveals that *Crataegus azarolus* var. *eu-azarolus* Maire has the efficiency to control hyperglycemia with its associated complications. This study is the first to evaluate antihyperglycemic and antihyperlipidemic potentials of 3β-O acetyl ursolic acid.

**Keywords:** *Crataegus azarolus* var. *eu-azarolus* Maire, 3β-O acetyl ursolic acid, Antimicrobial, Antihyperglycemic, Antihyperlipidemic

*Correspondence: eabugharbieh@sharjah.ac.ae
1Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
2Department of Pharmacology and Toxicology, Dubai Pharmacy College, Dubai, United Arab Emirates
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Dyslipidemia and increased susceptibility to infections are two typical complications of diabetes mellitus. High glucose levels are highly associated with immune system impairment, particularly on neutrophils [1]. Hyperglycemia reduces the phagocytic activity and ability of neutrophils to form extracellular traps to kill bacteria [1]. On the other hand, hyperglycemia due to both insulin deficiency and insulin resistance significantly affect the lipid metabolic pathways [2]. Diabetic patients usually experience various cardiovascular complications of which dyslipidemia represents a main risk factor [2].

There has been a noticeable increase in the use of both traditional home remedies and herbal medicine instead of relying on conventional treatments [3]. This has caused traditional medicine to become of worldwide importance, with medicinal and economic effects [4].

*Crataegus azarolus* is indigenous to the Mediterranean Basin. *Crataegus azarolus* var. *eu-azarolus* Maire is a low, dense, spiny tree with a beautiful inflorescence up to 6 m tall and with orange fruits [5]. Phytochemical investigation of the plant was performed mainly on the flowers. Antioxidant activity and phenolic composition of the flowers extract were studied [6]. No available literatures concerning the pharmacological activity and the phytochemical constituents of the leaves were found.

In folk medicine, genus *Crataegus* (commonly called hawthorn in English and Zaarour in Arabic) is used for curing several ailments viz. central nervous, reproductive, cardiovascular and immune systems [7]. It also showed anti-inflammatory, cytotoxic, antioxidant, gastroprotective, antimicrobial, cardioprotective, antidiabetic and anti-HIV activities [8–14].

Phytochemical investigations on genus *Crataegus* were mainly performed on the leaves, flowers and berries. The isolated compounds were: oligomeric procyanidins, bioflavonoid, polysaccharides, catecholamines, vitamin C, saponins, tannins, cardiotoxic amines, purine derivatives and ursolic acid [8–10, 15–18].

This study aimed to explore the phytochemical composition of *Crataegus azarolus* var. *eu-azarolus* Maire leaves’ extract, assess its acute toxicity and investigate the free radical scavenging and therapeutic potentials particularly antimicrobial, antihyperglycemic and antihyperlipidemic activities.

Methods
**General**

Shimadzu 1700 spectrophotometer was used for UV absorption spectra. Melting points were determined on Electrothermo 9100 equipment. Mass spectra were measured on a Jeol Mass Spectrometer SSQ 7000, Digital DEC 300. NMR spectra were measured in DMSO or CD$_3$OD or CDCl$_3$; $^{1}$H–NMR spectra were obtained at 400 MHz and $^{13}$C-NMR spectra at 100 MHz on a JEOL GX-400 spectrometer with the chemical shifts (6 ppm) expressed relative to TMS as internal standard. Pre-coated silica gel 60 F$_{254}$ (Merck, Darmstadt, Germany) was used for the TLC analysis. Vacuum liquid chromatography (VLC) was performed on silica gel 60 GF (Merck, Darmstadt, Germany). Sephadex LH-20 (Sigma-Aldrich, St. Louis, Missouri, United States) and silica gel 100 G$_{18}$-Reversed Phase (Fluka, Switzerland) were also used. Analysis of phenolics was performed on Hewlett Packard HPLC (HP 1050HPLCDADw/Data System) equipped with a HypersIL-ODS (4.6 X 250 mm, 5 μm) column and a UV detector.

**Plant material**

Leaves of *Crataegus azarolus* var. *eu-azarolus* were collected during the fruiting stage in July 2012 from plants cultivated in Nablus, Palestine. The plant was identified by Professor Hassnaa Ahmed Hosny, Department of Botany, Faculty of Science, Cairo University, Egypt. A voucher specimen has been kept at the Herbarium of the Department of Pharmacognosy, Faculty of Pharmacy, Cairo University.

**Chemicals, drugs and biochemical kits**

All solvents were of analytical grade and obtained from Fisher Scientific. Sodium carboxymethylcellulose (CMC), 2,2-diphenyl-1-picrylhydrazyl (DPPH), gentamicin, fluconazole, alloxan, glibenclamide, cholesterol, lovastatin, orlistat, procaine pancreatic lipase type II, p-nitrophenyl butyrate (PNPB) and HMG-CoA reductase assay kit were purchased from Sigma-Aldrich (St. Louis, Missouri, United States). Folin-Ciocalteu reagent was obtained from Merck (Darmstadt, Germany). Lipid profile assessment kits including total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were purchased from Abcam-Cambridge, UK. Glucose estimation kit (kit Glu 1108, Test Strips, One Touch, Lifescan) was used to evaluate the blood glucose level.

**Plant leaves extraction**

*Selection of best extraction solvent for phenolic contents*

Acetone, ethyl acetate, Methanol and 70% ethanol were used individually for the extraction of the powdered leaves material (each 100 g). Spectrophotometric methods were used to determine the phenolic and the flavonoid contents. The experiments were carried out in triplicate.

**Spectrophotometric determination of total phenolic and flavonoid contents**

Folin-Ciocalteu reagent was used to measure the phenolic content according to Oktay et al. [19]. Different
concentrations from gallic acid (10–50 µg/mL) were prepared for the standard calibration curve. The absorbance was determined at 750 nm. Results were calculated as mg gallic acid/g dry plant weight equivalent.

Aluminum chloride was used to assess the total flavonoid contents of the different extracts according to the procedure described by Dewanto et al. [20]. Serial dilutions of quercetin were used for preparation of the standard calibration curve. The absorbance was measured at 510 nm. All the experiments were carried out in triplicate.

**RP- HPLC analysis**

Phenolic composition of *C. azarolus* var. *eu-azarolus* leaves was investigated in aliquots (1 g, each) of the methanolic extract of the plant via RP-HPLC [21, 22] based on the method previously described by the authors [23]. For the phenolic acids composition, the UV detector was set at 280 nm while for flavonoids composition the UV detector was adjusted at 330 nm. Quantification was based on peak area calculation and was done in triplicate.

**Large scale extraction and fractionation**

Air-dried powdered leaves of *C. azarolus* var. *eu-azarolus* (2.5 Kg) were extracted at room temperature by maceration in ethanol (70%, 10 L × 3). The ethanolic extract was evaporated under reduced pressure at temperature 55 °C to provide 280 g residue. 200 g residue were successively fractionated with different solvents according to the polarity viz. *n*-hexane, chloroform and *n*-butanol saturated with water; while the remaining residual amount was saved for biological evaluation. Partitioning the ethanolic extract with different solvents yielded 20, 15 and 18 g of dried extractive respectively.

**Isolation of the constituents of the n-butanol extract**

An accurately weighed amount of the chloroform extract (13.0 g) was applied on silica gel 60 GF VLC column (25 X 5 cm). Gradient elution was performed using hexane-chloroform, chloroform-ethyl acetate mixtures and ethyl acetate. Fractions (100 mL each) were gathered and monitored by TLC using different mobile phase (System A, chloroform-methanol 9.5:0.5 and System B, ethyl acetate) upon rechromatography on a silica gel 100 C18-RP column under reduced pressure (20 X 1.5 cm) using methanol–water 1:1 as eluent, resulted in isolation of compounds 1 and 2.

F5: (1.2 g; 2 spots, Rf values 0.77 and 0.47, System B) was exposed to three columns the first and second were on sephadex LH-20 (35 X 3 cm; elution, methanol–water 9:1 then 8:2) the third one was a silica gel 100 C18-RP under reduced pressure (20 X 1.5 cm; elution, methanol–water 1:1) to afford compound 3.

**Antioxidant activity**

**DPPH radical scavenging assay**

Ethanol (70%), methanol, acetone, and ethyl acetate were used individually to extract the leaves. The free radical-scavenging activity was assessed by DPPH radical [24]. Different concentrations of leaves extracts concentrations (3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 µg/mL) and ascorbic acid (AA), as standard compound, were analyzed in triplicate. The percentage inhibition of DPPH radical was calculated as follow:

\[
\text{% inhibition} = \frac{[A_0 - (A_1 - A_2)]}{A_0} \times 100%. \\
A_0: \text{control absorbance}, \ A_1: \text{absorbance of the sample}, \ A_2: \text{absorbance of the sample in ethanol without DPPH.}
\]

**Biological study**

**Microorganisms**

Three bacterial strains and one fungus, were kindly provided by Rashid hospital (Dubai-UAE) and were used
for the antimicrobial screening. This included one representative of the Gram-positive group (*Staphylococcus aureus* RMTCC 3161), two representatives of the Gram-negative group (*Escherichia coli* RMTCC 2682 and *Pseudomonas aeruginosa* RMTCC 1687) and one fungus (*Candida albicans* RMTCC 5122). Microorganisms were grown on appropriate media: nutrient agar for *S. aureus* and *P. aeruginosa*, MacConkey agar for *E. coli* and Sabouraud dextrose agar for *C. albicans*.

**Antimicrobial activity**

The ethanolic extract, and its fractions, n-hexane, chloroform and n-butanol as well as the isolated compounds of *C. azarolus* at doses of 375 μg/mL for each extract, and 140 μg/mL for the isolated compounds were subjected to in-vitro qualitative screening, for evaluation of their antimicrobial potentialities. The agar diffusion technique was used [25]. Solubilization of the samples was assisted by sterile DMSO. The effects were compared with gentamicin (30 μg/mL) and antifungal, fluconazole (30 μg/mL). Diameters of zones of inhibition (in mm) were taken as a measure for the growth inhibitory activity against the selected strains.

**Experimental animals**

Male albino mice (30 ± 5 g) were used for acute toxicity and antihyperglycemic studies. Antihyperlipidemic experiments were performed on Sprague Dawley rats weighing 210 ± 5 g. All animals were kept under standard conditions, fed with regular diet and water supplied ad libitum. Mice were accommodated for 1 week prior to the experiments. All animal investigations were accepted from the Ethical Research Committee of the Dubai Pharmacy College, Dubai UAE and done according to the ethical standards of laboratory animals [26].

**Acute oral toxicity study**

LD$_{50}$ was determined by probit test [27]. Mice were divided into five groups (10 each) and they received various oral doses of the ethanolic extract (250, 500, 1000, 2500 and 5000 mg/kg). Later, they were observed over 72 h for any signs of morbidity or abnormal behavior and their death was recorded [27].

**Evaluation of antihyperglycemic activity**

*Induction of diabetes in mice*

One night before the induction of hyperglycemia, the animals were kept fasted but given water ad libitum. The next morning, animals were injected 150 mg/kg alloxan monohydrate solution in acetate buffer (0.15 M, pH 4.5) intraperitoneally. The animals were observed over a week and their blood glucose values were measured. Mice with blood glucose levels between 180 and 360 mg/dL were assigned diabetic and were used later for further studies [28].

**Oral glucose tolerance test**

Animals were divided into four groups (n = 6 each). The mice were fasted for 18 h and provided water ad libitum. Each animal serves as its own control, Group I received only glucose at dose of 2 g/kg. Groups II and III received 250 and 500 mg/kg of the ethanolic leaves extract respectively, while group IV received the isolated compound in a dose of 50 mg/kg. All the tested samples were given orally 90 min before the glucose dose (2 g/kg, p.o.). Levels of blood glucose were calculated before and subsequently at 30, 60, 120 and 240 min after the administration of glucose dose. Blood glucose was measured by glucose estimation kit.

**Experimental procedure**

The diabetic animals were divided into five groups (n = 6 each). Group I kept as control, group II received 5 mg/kg glibenclamide as positive control, groups III and IV received the extract at doses of 250 and 500 mg/kg respectively, and group V received the isolated compound (2) at dose of 50 mg/kg. Levels of the blood glucose were measured pre and post (120 and 240 min) the treatment.

**Evaluation of antihyperlipidemic activity**

*Induction of hyperlipidemia in rats*

The rats were fed daily by means of gavage tube with cholesterol at 25 mg/kg suspended in coconut oil given at 10 mL/kg daily for 30 days [29].

**Experimental procedure**

The animals were grouped into five treatment categories (n = 6, each), as following: Group I, kept as control; group II received daily 1% w/v sodium CMC suspension. Animals in groups II-V were hyperlipidemic and received daily cholesterol (25 mg/kg/day) in oil at 10:00 am. Group II represented the hyperlipidemic group, group III served as positive control and received lovastatin (10 mg/kg/day) at 3:00 pm. Similarly groups IV and V were given the ethanolic leaves extract at doses of 250 and 500 respectively at 3:00 pm. For a period of 30 days, the original and the final body weights and food intake of rats were monitored. After this period, the fasted rats were sacrificed. Under ether anesthesia, samples of the blood were gathered by cardiac puncture. Lipid profile test was done including TC, HDL-C, LDL-C, VLDL-C and TG.

Additionally, cardiac risk indicators were calculated by the “Atherogenic Index” TC: HDL-C ratio and LDL-C: HDL-C ratio.
In-vitro evaluation of the effect of the ethanolic extract and its isolated compound (2) on pancreatic lipase and HMGCoA reductase activities

In-vitro lipase inhibitory effect of the ethanolic leaves extract and the isolated compound (2) was assessed according to the method previously described [30]. The final concentrations of the tested samples of the plant extract and isolated compound were ranged from 50 to 500 μg/mL and 20–200 μg/mL respectively.

The following formula was used to calculate the percentage inhibitory activity (I):

\[
I = 100 - [(B - b)/(A - a) \times 100]
\]

Where A: activity without inhibitor; a: negative control in absence of inhibitor; B: activity in presence of inhibitor; and b: negative control in presence of inhibitor.

Orlistat and DMSO were used as positive and negative control respectively and their activities were also tested. For the in-vitro evaluation of HMG-CoA inhibitory activity, similar concentrations range of the plant extract and isolated compound were used. Pravastatin was used as standard drug with concentrations ranged from 0.1–2.5 μg/mL according to the method previously described [31]. HMG-CoA reductase inhibitory activity was calculated by using the following formula:

Inhibitory activity (I %) = (\(\Delta\) Absorbance control - \(\Delta\) Absorbance test)/\(\Delta\) Absorbance control) × 100

Statistical analysis

The results were expressed as mean ± S.E.M (Standard Error Mean). Data was analyzed by GraphPad Software version 6.00 (San Diego, CA). One-Way ANOVA followed by Bonferroni’s multiple comparison tests against the control was performed. For repeated measures in glucose tolerance test, two-way ANOVA assessed the interactive and independent effects of treatment and time. *P* values < 0.05 were considered significant. IC\(_{50}\) values for the DPPH radical scavenging, pancreatic lipase inhibition and HMG-CoA inhibition assays were determined from the dose–response curves using a linear regression analysis. For in-vitro evaluation of pancreatic lipase and HMG-CoA inhibition activities, inhibition of less than 40% was considered irrelevant and was selected as a cutoff point.

Results

Spectrophotometric determination of total phenolic and flavonoid contents

Different solvents were used for leaves extraction for the flavonoid and the phenolic contents to select the safest and the most effective extracting solvent as shown in Table 1. Spectrophotometric analysis revealed that ethanol was the best solvent to extract both flavonoids and phenolic acids.

| Solvent                      | Extraction yield (%)* | Total flavonoid content (mg quercetin/g) | Total phenolic content (mg GAE/g) |
|------------------------------|-----------------------|-----------------------------------------|----------------------------------|
| Ethanol                      | 20.0 ± 1.2            | 1.5 ± 0.2                                | 1.5 ± 0.6                        |
| Methanol                     | 12.3 ± 1.7            | 1.1 ± 0.3                                | 1.3 ± 0.7                        |
| Ethanol                     | 9.7 ± 0.8             | 0.9 ± 0.0                                | 0.6 ± 0.0                        |
| Acetone                     | 2.4 ± 0.3             | 0.7 ± 0.1                                | 0.1 ± 0.0                        |

*Expressed as 100 x (g dry extract/g dry leaves)

RP-HPLC analysis

RP-HPLC analyses of the methanolic leaves extract of C. azarolus var. eu-azarolus Maire revealed that 11 components were identified at \(\lambda=280\) nm (corresponding to 37.73% of the total composition, Table 2) among which 8 were phenolic acids (30.77%) with prevalence of salicylic acid (11.91%) and ellagic acid (9.78%) and one flavonoid (catechin) besides the diphenol, catechol; meanwhile, at \(\lambda=330\) nm, 7 components were known (Table 3); six of which were flavonoidal compounds with the major rutin (6.50%). (RP-HPLC chromatograms are available as Additional file 1).

Isolation of the constituents of the chloroform and n-butanol extracts

Isolated compounds

Compound 1 (ursolic acid): Molecular formula, C\(_{30}\)H\(_{48}\)O\(_3\); white powder; 20 mg; soluble in chloroform; RF: 0.70 (System A); gave positive test for sterols and/or triterpenes; m.p., 286 °C; El-MS m/z (% rel. Intensity) 456; 1HNMR (400 MHz, CDCl\(_3\)): 8H 0.79, 0.98, 0.97, 1.0 and 1.2 (15 H, 5 s, all CH\(_3\)), 0.93, (3H, d, \(J = 6.4\) Hz, H-30), 0.94 (3H, d, \(J = 6\) Hz, H-29), 1.62 (2H, m, H-21), 1.38 (2H, m, H-16), 2.10 (d, 1H, \(J = 15\) Hz, H-18), 3.32 (1H, dd, \(J = 10.8, 4.4\) Hz, H-3), 5.30 (1 H, t; \(J = 3.6\) Hz, H-12).

### Table 2 RP-HPLC analysis of phenolics components of C. azarolus var. eu-azarolus leaves extract at \(\lambda = 280\) nm

| Retention time | Identified component   | Relative area % |
|----------------|----------------------|----------------|
| 6.81           | Pyrogallol           | 0.17           |
| 6.92           | Gallic acid          | 0.24           |
| 8.235          | Protocatechuic acid  | 3.95           |
| 8.444          | Catechin             | 4.82           |
| 8.593          | Chlorogenic acid     | 2.97           |
| 8.950          | Catechol             | 1.90           |
| 10.040         | Caffeic acid         | 0.75           |
| 11.620         | Ferulic acid         | 0.75           |
| 12.466         | Salicylic acid       | 11.91          |
| 12.943         | Ellagic acid         | 9.78           |
| 14.980         | Cinnamic acid        | 0.47           |

Total identified constituents 37.73
Compound 2 (3β-O acetyl ursolic acid): Molecular formula, C_{32}H_{50}O_{4}; white powder; 300 mg; soluble in chloroform; Rf 0.60 (System A); gave positive test for sterols and/or triterpenes; m.p., 268–270 °C; EI-MS m/z (% rel. Intensity) 498; 1HNMR (400 MHz, DMSO): δH 0.76, 0.85, 0.87, 1.00, 1.1 (15 H, 5 s, CH₃), 0.87 (3H, δ, J = 6.4 Hz H-3, δ, J = 6 Hz H-29), 1.21 (2H, in H-21), 1.26 (2H, m, H-16), 2.15 (1H, d, J = 12 Hz, H-18), 2.41 (3H, s, OAc), 4.43 (1H, dd, J = 10.8, 4.4 Hz, H-3), 5.11 (1H, t, J = 3.6 Hz, H-12). 13C NMR data for compounds 1 and 2 were recorded in Table 4.

Compound 3 (ellagic acid): Molecular formula, C_{14}H_{6}O_{8}; yellow crystalline; 15 mg; soluble in methanol; Rf 0.47 (System B); gave positive test for FeCl₃; m.p., 370 °C, EI-MS m/z (% rel. Intensity) 302; colour in visible light, yellowish brown; Under UV light and under UV/ammonia, brown, UV λmax nm: CH₃OH, 253, 354; 1H NMR (400 MHz, CD₃OD): δH 7.49 (1H, s, H-5′′) and 7.67 (1H, s, H-5).

Compound 4 (quercetin 3-O-β-methyl ether): Molecular formula, C_{16}H_{12}O_{7}, yellow powder, 35 mg; soluble in methanol; Rf: 0.50 (System C); yellowish brown in visible light; brown under UV 365nm light and yellow under UV 365nm/NH₃, UV λmax nm: CH₃OH, 256, 294sh, 358; CH₃ONa, 270, 331, 407; AlCl₃, 274, 300sh, 336, 440; AlCl₃/HCl, 264, 300sh, 360, 402; NaOAc, 273, 323, 380; NaOAc/H₂BO₃, 262, 297sh, 380; 1HNMR, (400 MHz, CD₃OD): δH 3.84 (3H, s, OCH₃), 6.21 (1H, d, J = 2 Hz, H-6), 6.49 (1H, d, J = 2 Hz, H-8), 6.84 (1H, d, J = 8.4 Hz, H-5′′), 7.40 (1H, dd, J = 2.0, 8.0 Hz, H-6′′), 7.70 (1H, d, J = 2 Hz, H-2′′).

Compound 5 (rutin): Molecular formula C_{27}H_{30}O_{16}; yellow powder; 20 mg; soluble in methanol; Rf 0.38 (system B); m.p. 245 °C; brown in visible light, dull brown under UV_{365nm} and yellow under UV_{365nm}/NH₃; UV λmax nm: CH₃OH, 260, 266 sh, 300 sh, 356; CH₃ONa, 278, 327, 411; AlCl₃, 270, 301sh, 430; AlCl₃/HCl, 267, 298, 360 sh, 400; NaOOCCH₃, 269, 325, 390; NaOAc/H₂BO₃, 261, 300, 385; 1HNMR, (400 MHz, CD₃OD): δH 6.11 (1H, d, J = 2 Hz H-6), 6.31 (1H, d, J = 2 Hz, H-8), 6.78 (1H, d, J = 8.4 Hz, H-5′′), 7.57 (2H, d, J = 8.4 Hz, H-2′′, H-6′′); 3.33–3.67 (12H, m of sugar moieties), 4.41(1H, d, J = 1.5 Hz, Rham), 1.07 (3H, d, J = 6 Hz, CH-Rham), 5.2 (1H, d, J = 7.8 Hz, H-1 Glu).

Compound 6 (apigenin 7-O-β-D-glucopyranosyl(6→1)-α-L-rhamnopyranosyl): yellow powder; 15 mg; soluble in methanol; Rf: 0.22 (system B); brown in visible light, dull brown under UV_{365nm} and yellowish green under UV_{365nm}/NH₃; UV λmax nm: CH₃OH, 267, 335; CH₃ONa, 247 sh, 267, 300 sh, 385; AlCl₃, 272, 300, 350, 381; AlCl₃/HCl, 270, 300, 347, 380; NaOOCCH₃, 254 sh.

| Retention time | Identified component | Relative area |
|---------------|---------------------|--------------|
| 3.83          | Quercetin           | 0.01         |
| 11.78         | Rosmarinic acid     | 0.89         |
| 12.44         | Rutin               | 6.50         |
| 14.576        | Naringenin          | 0.43         |
| 14.952        | Hispertin           | 0.80         |
| 16.167        | Apigenin            | 0.16         |
| 18.657        | Chrysin             | 0.82         |

Total identified constituents 9.61

### Table 3 RP-HPLC analysis of phenolics components of C. azarolus var. eu-azarolus leaves extract at λ = 330 nm

| Retention time | Identified component | Relative area % |
|---------------|---------------------|-----------------|
| 3.83          | Quercetin           | 0.01            |
| 11.78         | Rosmarinic acid     | 0.89            |
| 12.44         | Rutin               | 6.50            |
| 14.576        | Naringenin          | 0.43            |
| 14.952        | Hispertin           | 0.80            |
| 16.167        | Apigenin            | 0.16            |
| 18.657        | Chrysin             | 0.82            |

Total identified constituents 9.61

### Table 4 13C NMR (100 MHz) data of compounds 1 and 2

| NO. | C     | Compound 1 (CDCl₃) | Compound 2 (DMSO) |
|-----|-------|--------------------|-------------------|
| 1   | 38.6  | 39.0               |
| 2   | 28.1  | 28.1               |
| 3   | 78.5  | 79.8               |
| 4   | 38.8  | 38.5               |
| 5   | 55.2  | 55.3               |
| 6   | 18.3  | 18.4               |
| 7   | 32.7  | 32.7               |
| 8   | 39.3  | 39.5               |
| 9   | 47.6  | 47.4               |
| 10  | 37.1  | 37.0               |
| 11  | 23.8  | 23.7               |
| 12  | 125.6 | 125.8              |
| 13  | 140.6 | 138.9              |
| 14  | 41.7  | 42.1               |
| 15  | 27.7  | 28.0               |
| 16  | 24.6  | 24.4               |
| 17  | 47.5  | 47.5               |
| 18  | 53.6  | 53.0               |
| 19  | 39.4  | 39.4               |
| 20  | 39.1  | 39.2               |
| 21  | 31.8  | 30.7               |
| 22  | 37.0  | 37.4               |
| 23  | 28.5  | 29.0               |
| 24  | 16.0  | 15.6               |
| 25  | 15.6  | 16.5               |
| 26  | 17.1  | 17.5               |
| 27  | 23.9  | 23.3               |
| 28  | 180.0 | 182.0              |
| 29  | 17.1  | 17.5               |
| 30  | 21.2  | 21.5               |
| 31  | OAc   | 22.3               |
| 32  | CH₃COO|                   |

Abu-Gharbieh and Shehab BMC Complementary and Alternative Medicine (2017) 17:218
Compounds 1 and 2 gave positive Salkoweski reactions confirming their triterpenoidal nature [32]. 1H- and 13C NMR spectra showed that compounds 1 and 2 were pentacyclic triterpene. Compound 1 was identified as ursolic acid from their physical properties and different spectral data (1H–NMR and 13C–NMR) [33, 34]. The structure of compound 3 was identified as ellagic acid from its physical properties and different spectroscopic spectra (UV and 1H–NMR) [35].

Table 5 13C NMR (100 MHz) data of compounds 4–6

| NO. C | Compound 4 CD3OD | Compound 5 CD3OD | Compound 6 CD3OD |
|-------|------------------|------------------|------------------|
| 2     | 155.3            | 151.7            | 162.1            |
| 3     | 137.3            | 134.2            | 103.0            |
| 4     | 178.2            | 178.0            | 180.0            |
| 5     | 161.0            | 161.6            | 151.1            |
| 6     | 98.2             | 98.5             | 103.1            |
| 7     | 1648             | 164.6            | 160.0            |
| 8     | 93.4             | 94.5             | 98.6             |
| 9     | 1574             | 156.6            | 157.0            |
| 10    | 103.3            | 103.3            | 108.4            |
| 1’    | 121.3            | 121.2            | 122.9            |
| 2’    | 115.1            | 116.2            | 129.7            |
| 3’    | 144.7            | 145.5            | 116.4            |
| 4’    | 148.4            | 148.4            | 116.1            |
| 5’    | 115.2            | 116.1            | 116.4            |
| 6’    | 121.5            | 122.2            | 129.2            |
| OCH3  | 58.2             |                  |                  |

1H and 13C–NMR spectra of compound 4 demonstrated a methoxy group at δH 3.84 and at δC 58.2 respectively attached at position 3; compound 4 was identified as quercetin 3-O-β-methyl ether [36]. The structure of compound 5 was identified as rutin from its physical properties and different spectral data (UV, 1H–NMR and 13C–NMR) [37].

The UV λmax (335 nm) of compound 6 suggested that it possesses a flavone substituted skeleton. This was confirmed from the 1H–NMR spectrum. The occurrence of two doublets signals at δH 6.51 and 6.86 (J = 2.2 Hz) indicated the presence of two meta protons at C-6 and C-8 of ring A respectively. In addition, 2 doublets appeared at δH 7.03 (2H, J = 8.8 Hz) and at δH 7.91 (2H, d, J = 9.1 Hz) indicated, H-3’, H-5’ and H-2’, H-6’, respectively and one singlet at δH 6.32 for H-3. The presence of two anomeric signals at δH 4.40 (d, J = 2 Hz) and at 5.1 (d, J = 7.3 Hz) with the methyl group of rhamnose at δH 1.07 (d, J = 6.0 Hz) indicated the presence of 2 sugar units linked to C-7 position with 6 → 1 linkage. The sugar moieties were identified as glucose and rhamnose (TLC of acid hydrolysate, 1H–NMR and 13C spectral data). Compound 6 could be identified as apigenin 7-O-β-D-glucopyranosyl (6 → 1)-α-L-rhamnopyranosyl (apigenin 7-O-rutinoside) [38]. Figure 1 is showing the chemical structure of the isolated compounds.

Antioxidant activity

DPPH free radical scavenging activity

DPPH free radical scavenging effects of the extracts were tested and the results are presented in Fig. 2. Both ethanolic and methanolic extracts showed the highest activity as revealed in Fig. 2. IC50’s of the leaves extracts were 129.2, 140.1, 164.1 and 262.3 μg/mL for the ethanolic, methanolic, ethyl acetate and acetone respectively. While for ascorbic acid, the IC50 was calculated to be 34.6 μg/mL.

Biological studies

Antimicrobial activity

Results displayed in Table 6 revealed that at the tested concentrations, the ethanolic extract as well its n-hexane fraction and the isolated compounds, ursolic acid, 3β-O acetyl ursolic acid and quercetin 3-O- methyl ether, showed variable antimicrobial activity against all the tested pathogenic strains bacteria and fungus. On the other hand, all the tested samples exhibited variable antibacterial activities with inhibition zones ranging from 18 to 28 mm in diameter against P. aeruginosa.

The isolated compound 2, 3β-O acetyl ursolic acid, demonstrated the highest growth inhibitory activity against all the tested microorganisms, followed by quercetin 3-O- methyl ether and lastly, ursolic acid.
Fig. 1 Compounds isolated from *C. azarolus* var. *euzarolus* leaves

Fig. 2 2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity of different concentrations of different extracts of *C. azarolus* var. *euzarolus*. Ascorbic acid (AA) was used as positive control. The data presented as mean ± SD
Acute oral toxicity study
The LD\textsubscript{50} of the ethanolic extract of \textit{C. azarolus} var. \textit{eu-azarolus} Maire was safe up to 5000 mg/kg. During the observation period, no signs of morbidity or behavioral alteration in any animals’ groups were noticed.

Evaluation of antihyperglycemic activity
Oral glucose tolerance test
Blood glucose levels of normal mice were significantly reduced after receiving the plant extract at different doses in a time- and dose-dependent manner as shown in Fig. 3. Both doses of the leaves, as well as the isolated compound, 3\(\beta\)-O acetyl ursolic acid, exhibited significant antihyperglycemic effect. The effect was significant at 30, 120 and 240 min. Noticeable significant decrease in level of glucose was noticed at 30 min with the leaves extract at both doses as well as 3\(\beta\)-O acetyl ursolic acid at dose of 50 mg/kg \((p < 0.01)\). This marked improvement in glucose tolerance was continued over the tested time.

Antihyperglycemic activity of the ethanolic extract and 3\(\beta\)-O acetyl ursolic acid on blood glucose levels in diabetic mice
The basal glycaemia was 241.7 ± 1.7 mg/dl for the diabetic control mice. There was no statistical difference between the glycaemic levels of the studied groups at time 0, \((p > 0.05)\).

The anti-hyperglycemic activity of the ethanolic extract and the isolated compound (2) on the fasting blood sugar levels of diabetic mice is shown in Fig. 4. In diabetic mice, treatment of \textit{C. azarolus} var. \textit{eu-azarolus} leaves extract at dose of 250 and 500 mg/kg significantly lowered the basal level of blood glucose at 120 and 240 min \((p < 0.01)\). A highly significant decrease of the blood glucose level was observed with 3\(\beta\)-O acetyl ursolic acid at the same timing intervals, \(p < 0.001\).

| Tested sample            | \textit{S. aureus} (zone of inhibition, mm) | \textit{P. aeruginosa} (zone of inhibition, mm) | \textit{E. coli} (zone of inhibition, mm) | \textit{C. albicans} (zone of inhibition, mm) |
|-------------------------|---------------------------------------------|-----------------------------------------------|------------------------------------------|---------------------------------------------|
| Ethanol extract         | 9.0 ± 1.1                                   | 22.0 ± 2.4                                    | 14.0 ± 1.2                               | 5.0 ± 1.2                                   |
| n-hexane                | 10.0 ± 1.8                                  | 24.0 ± 1.6                                    | 25.0 ± 2.6                               | 7.0 ± 0.7                                   |
| Chloroform              | 7.0 ± 0.7                                   | 25.0 ± 3.3                                    | 22.0 ± 3.0                               | -                                           |
| n-butanol               | -                                           | 20.0 ± 2.1                                    | 21.0 ± 2.1                               | -                                           |
| Ursolic acid            | 23.0 ± 2.6                                  | 24.0 ± 2.4                                    | 22.0 ± 1.9                               | 13.0 ± 1.2                                  |
| 3\(\beta\)-O acetyl ursolic acid | 30 ± 3.4                                  | 28.0 ± 3.1                                    | 29.0 ± 2.3                               | 15.0 ± 0.8                                  |
| Ellagic acid            | -                                           | 23.0 ± 3.5                                    | -                                        | -                                           |
| Quercetin 3-O- methyl Ether | 25.0 ± 3.1                                  | 26.0 ± 2.9                                    | 25.0 ± 2.8                               | 21.0 ± 2.3                                  |
| Rutin                   | 6.0 ± 2.5                                   | 20.0 ± 1.8                                    | -                                        | -                                           |
| Apigenin7-O-rutinoside  | 6.0 ± 1.9                                   | 18.0 ± 1.6                                    | -                                        | -                                           |
| Gentamicin              | 20.0 ± 2.7                                  | 18.0 ± 1.9                                    | 22.0 ± 3.4                               | -                                           |
| Fluconazole             | -                                           | -                                             | 25 ± 2.5                                 |                                             |

Table 6 Antimicrobial activity of the ethanolic extract, fractions and isolated compounds of \textit{C. azarolus} var. \textit{eu-azarolus} leaves

Fig. 3 Effect of ethanolic extract of \textit{C. azarolus} var. \textit{eu-azarolus} leaves and 3\(\beta\)-O acetyl ursolic acid on glucose tolerance test, *\(p < 0.01\), **\(p < 0.001\).

Group I received 2 g/kg glucose only. Groups II and III received 250 and 500 mg/kg of the plant extract respectively, and group IV received 3\(\beta\)-O acetyl ursolic acid.
Antihyperlipidemic activity

Body weight Compared to cholesterol induced hyperlipidemic control group (group II), lovastatin treated group showed that the reference has no effect on the body weight ($p > 0.05$). On the other hand, groups received the ethanolic leaves extract showed a significant reduction in the percentage increment in body weight in day 15 and 30 ($p < 0.01$) as shown in Table 7.

Effect of the ethanolic extract on serum lipid profile in hyperlipidemic rats In hyperlipidemic model, groups treated with the ethanolic leaves extract and lovastatin showed significant reduction in TC, TG, LDL-C, and VLDL-C levels. In addition, serum HDL-C level was increased as compared to the control group (Table 8). Treated Groups with lovastatin and the leaves ethanolic extract demonstrated remarkable decrease in the “Atherogenic Index” and LDL-C: HDL-C risk ratios.

In-vitro effect of the ethanolic extract and 3β-O acetyl ursolic acid on pancreatic lipase and HMGCoA reductase activities C. azarolus var. eu-azarolus ethanolic extract at concentrations of 50–500 μg/mL reduced the activity of pancreatic lipase in-vitro. Significant reduction was noticed at concentrations of 200–500 μg/mL of 40.6–98.5% respectively with IC$_{50}$ 252.3 μg/mL compared to orlistat (IC$_{50}$ 0.59 μg/mL). Moreover, 3-β-O acetyl ursolic acid at concentrations between 80 and 200 μg/mL significantly reduced the pancreatic lipase activity with 42.4–99.6% and the IC$_{50}$ was 93.6 μg/mL. On the other hand, the plant extract showed moderate inhibition of HMGCoA reductase activity at concentrations between 350 and 500 μg/mL of 42.6–60% with IC$_{50}$ 394.1 μg/mL compared to pravastatin that has IC$_{50}$ of 0.71 μg/mL. 3-β-O acetyl ursolic acid didn’t show any significant inhibition of HMGCoA at the tested concentration.

Discussion Diabetes Mellitus and other hyperglycemic disorders are complicated conditions associated with high prevalence of infection, dyslipidemia, hypertension and renal failure. The aim of this study was to find a standard plant extract that has the potential to control hyperglycemia with its associated complications, and to isolate and identify the active components that are responsible for those activities.

Results of total phenolic and flavonoid contents revealed that ethanol was the best solvent to extract both flavonoid and phenolic acids. Therefore, ethanol had been selected for further investigations. RP- HPLC analysis of the phenolics demonstrated high contents of rutin, salicylic and ellagic acids in the plant. Six compounds belonging to triterpenes and phenolic were isolated from chloroform and n-butanol fractions for the first time from C. azarolus var. eu-azarolus Maire. Ursolic acid is a triterpenoidal compound that finds in medicinal herbs, other plants and foods [39]. Ursolic acid showed anti-inflammatory, hepatoprotective, antihyperlipidemic, anticancer, inhibition of lipid peroxidation and antimicrobial activities [39–43]. Most of the available scientific papers are concerned about the activity of ursolic acid with no data regarding the antihyperglycemic and antihyperlipidmic of its acetate.

![Fig. 4](image_url)

**Table 7** Percentage increment in the experimental groups’ body weight for 30 days treatment period

| Group | Treatment (p.o.) | Day 0       | Day 15      | Day 30       |
|-------|-----------------|-------------|-------------|-------------|
| I     | 1% w/v sodium CMC | 211.3 ± 3.6 | 236.1 ± 4.3 | 253.2 ± 3.4 |
|       |                  | (+11.9 ± 0.5) | (+20.2 ± 0.4) |       |
| II    | Cholesterol     | 209.3 ± 28  | 250.4 ± 3.6 | 273.1 ± 4.6 |
|       |                  | (+198.0 ± 0.5) | (+305.0 ± 0.3) |       |
| III   | Cholesterol + lovastatin | 212.4 ± 3.6 | 252.1 ± 2.4 | 272.1 ± 3.4 |
|       |                  | (+187.0 ± 0.3) | (+281.0 ± 0.6) |       |
| IV    | Cholesterol + plant extract 250 mg/kg | 211.8 ± 4.2 | 244.4 ± 5.1 | 250.1 ± 3.5 |
|       |                  | (+154.0 ± 0.3) | (+181.0 ± 0.6) |       |
| V     | Cholesterol + plant extract 500 mg/kg | 210.6 ± 5.3 | 241.1 ± 4.3 | 247.8 ± 5.3 |
|       |                  | (+145.0 ± 0.2) | (+173.0 ± 0.8) |       |

* $p < 0.01$ vs group I; ** $p < 0.05$ and 0.01 vs cholesterol induced hyperlipidemic control group respectively.


| Group | Total cholesterol (mg/dl) | Triglyceride (mg/dl) | HDL-C (mg/dl) | LDL-C (mg/dl) | VLDL-C (mg/dl) | Atherogenic index | LDL-C/HDL-C |
|-------|--------------------------|---------------------|--------------|--------------|---------------|-----------------|-------------|
| I     | 61.7 ± 2.4               | 60.5 ± 5.6          | 36.3 ± 1.1   | 22.0 ± 0.7   | 12.4 ± 0.5     | 1.7 ± 0.3       | 0.6 ± 0.02   |
| II    | 58.0 ± 2.1               | 57.0 ± 4.8          | 35.1 ± 1.0   | 21.1 ± 0.8   | 11.9 ± 0.4     | 1.6 ± 0.2       | 0.5 ± 0.02   |
| III   | 54.5 ± 2.3               | 53.5 ± 4.9          | 33.9 ± 0.9   | 20.7 ± 0.6   | 11.5 ± 0.3     | 1.5 ± 0.1       | 0.4 ± 0.02   |
| IV    | 51.9 ± 2.0               | 51.0 ± 4.5          | 32.7 ± 0.8   | 19.9 ± 0.5   | 11.0 ± 0.2     | 1.4 ± 0.1       | 0.3 ± 0.02   |
| V     | 49.0 ± 2.5               | 48.0 ± 4.4          | 31.5 ± 0.7   | 19.1 ± 0.4   | 10.5 ± 0.1     | 1.3 ± 0.0       | 0.2 ± 0.02   |

Table 1: Effect of C. azarolus var. eu-azarolus on serum lipid profile, Atherogenic Index and LDL-C/HDL-C ratio in hyperlipidemic and diabetic rats.
Additionally, it reduces cellular cholesterol and triglyceride levels in hepatocytes, possibly by increasing the uptake and oxidation of fatty acid and by inhibiting their synthesis [59]. Interestingly, the enzymatic assay confirmed the inhibitory activity of the ethanolic extract and 3-β-O acetyl ursolic acid on pancreatic lipase. Hence, the antihyperlipidemic effect of the ethanolic extract and attenuation of body weight gain might be due to its inhibitory action on pancreatic lipase.

Conclusion
The current study demonstrates the efficiency of the leaves extract of C. azarolus var. eu-azarolus Maire in controlling hyperglycemia with its associated complications such as infection and dyslipidemia. This multiple pharmacological profile might be due to the synergistic effect of its bioactive constituents including triterpenes, particularly ursolic acid and its acetyl derivative, and the phenolic compounds particularly, quercetin 3-O-β methyl ether, rutin and apigenin 7-O-rutinoside. This study is unique in the sense that it is the first to evaluate the antihyperglycemic and antihyperlipidemic potentialities of 3β-O acetyl ursolic acid.

Additional file

Additional file 1: RP-HPLC chromatograms of the phenolic contents at λ =280 and 330 nm. (DOCX 566 kb)

Abbreviations
DPPH: 2, 2-diphenyl-1-picrylhydrazyl; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; PPAR: Peroxisome proliferator-activated receptors; TC: Total cholesterol; TG: Triglycerides; VLDL-C: Very low density lipoprotein cholesterol

Acknowledgement
The authors are indebted to Prof. S. A. Khan, Dean of the Dubai Pharmacy College, in accomplishing this work. We would like also to thank Mrs. Salam Estwani, Sara Safa, Heba Basmaji, Manal Khalid, Asmaa Rami, Fatima Elzahra Kamal and Hala Azam for their assistance in biochemical analysis work.

Funding
This research received no specific grant from any funding.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.

Authors’ contributions
EAG and NGS designed the experimental work, wrote the manuscript. Specifically, research idea and in-vitro, in-vivo experiments, statistical data and results analysis done by Dr. EAG. Dr. NGS was responsible for the leaves extraction, measurement of total phenolic and flavonoid contents, fractionation, isolation of the active constituents, interpretation of RP-HPLC and NMR results. Both authors approved the final article.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval
All animal investigations were performed according to the ethical standards for the proper care and use of laboratory animals and upon approval of the Ethical Research Committee at Dubai Pharmacy College, Dubai, UAE.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. 2Department of Pharmacology and Toxicology, Dubai Pharmacy College, Dubai, United Arab Emirates. 3Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Giza, Egypt.

Received: 20 December 2016 Accepted: 6 April 2017
Published online: 18 April 2017

References
1. Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci. 2016;351:201–11.
2. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–68.
3. World Health Organisation. WHO traditional medicine strategy: 2014–2023. http://www.who.int/medicines/publications/traditional/trm_strategy14_23/en. Accessed 2 May 2016.
4. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21:559.
5. Christensen KL. Revision of Crataegeus sect. Crataegus and Nothocereus. Crataeginaeae (Rosaceae: Maloideae) in the old world. Arne Soc Plant Taxonom. 1992;35:199.
6. Bahri-Sahloul R, Ben Fredj R, Boughalleb N, et al. Phenolic composition and antioxidant and antimicrobial activities of extracts obtained from Crataegeus azarolus L. var. aronia (Willd) Batt. Ovaries Calli. J Botany. 2014;2014:11.
7. Khalil R, Abuharfeil N, Shabsoug B. The effect of Crataegeus aronia acaica extract in rabbits fed with high cholesterol diet. Eur J Scientific Res. 2008;22:352–60.
8. Bahoron T, Trotin F, Pommery J, Vasseur J, Pinks M. Antioxidant activities of Crataegus monogyna extracts. Planta Med. 1994;60:239–8.
9. Kao ES, Wang CJ, Lin WL, Yin YF, Wang CP, Tseng TH. Anti-inflammatory potential of flavonoid contents from dried fruit of Crataegeus pinnatifida in vitro and in vivo. J Agric Food Chem. 2005;53:430–6.
10. Kumar D, Aya V, Bhat ZA, Khan NA, Prasad DN. The genus Crataegus: chemical and pharmacological perspectives. Rev Bras. 2012;22:187–200.
11. Bennmalek Y, Yahia OA, Belkebir A, Fardeau ML. Anti-microbial and anti-oxidant activities of Illicium verum, Crataegus oxyacantha spp monogyna and Allium cepa red and white varieties. Bioengineering. 2015;3:244–8.
12. Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evid Based Complement Alternat Med. 2013;2013:149363.
13. Tassell MC, Kingston R, Gilroy D, Lehane M, Furey A. Hawthorn (Crataegus spp) in the treatment of cardiovascular disease. Pharmacogn Rev. 2010;4:32–41.
14. Chowdhury SS, Islam MN, Jung HA, Choi JS. In vitro anti-diabetic potential of the fruits of Crataegeus pinnatifida. Res Pharm Sci. 2014;9:11–22.
15. Sokol-letowska A, Oszmianski J, Wojdylo A. Antioxidant activity of the phenolic compounds of hawthorn, pine and skullcap. Food Chem. 2007;103:853–9.
16. Liu P, Kallio H, Lu D, Zhou C, Yang B. Quantitative analysis of phenolic compounds in Chinese hawthorn (Crataegus spp) fruits by high performance liquid chromatography-electrospray ionisation mass spectrometry. Food Chem. 2011;127:1370–7.
17. Baram AH, Banaz J. Determination of Flavonoids in the leaves of hawthorn (Crataegus Azorialis) of Iraqi Kurdistan region by HPLC analysis. Int J Biosci Biochem Biotechnol. 2013;3:67–70.
18. Duke JA. Handbook of Phytochemical constituents of GRAS herbs and other economic plants (and database) Boca Raton. Florida: CRC Press, Inc; 1992.
19. Oktay M, Gulec I, Kufrevigolu OI. Determination of in vitro antioxidant activity of fennel (Foeniculum vulgare) seed extracts. LWT Food Sci Technol. 2003;36:263–71.
20. Dewanto V, Wu X, Adorn KK, Liu RH. Thermal processing enhances the nutritional-value of tomatoes by increasing total antioxidant activity. J Agric Food Chem. 2002;50:3010–4.
21. Goup Y, Hugues M, Boivin P, Amiot MJ. Antioxidant composition and activity of barley (Hordeum vulgare) and malt extracts and of isolated phenolic compounds. J Sci Food Agric. 1999;79:1625–34.
22. Mattila P, Astola J, Kumpulainen J. Determination of Flavonoids in plant material by HPLC with diode-Array and electro-Array detections. J Agric Food Chem. 2000;48:5834–41.
23. Shehab NG, Abu-Gharbieh E, Bayoumi FA. Impact of phenolic composition on hepatoprotective and antioxidant effects of four desert medicinal plants. BMC Complement Altern Med. 2015;15:401.
24. Cheng Z, Moore J, Yu L. High-throughput relative DPPH radical scavenging capacity assay. J Agric Food Chem. 2006;54:7429–36.
25. Lorian V. Antibiotics in laboratory medicine. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2005.
26. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 2011.
27. Lorke D. A new approach to practical acute toxicity testing. Arch Toxicol. 1986;54:275–87.
28. Syiem D, Syngai G, Khup PZ, Khongwir BS, Kharbuli B, Kayang H. Hypoglycemic effects of Potentilla fulgens L. in normal and alloxan-induced diabetic mice. J Ethnopharmacol. 2002;83:55–61.
29. Arichi H, Kimura Y, Okuda H, Baba K, Kozawa M, Arichi S. Effects of stilbene components of the roots of Polygonum cuspidatum Sieb. Et Zucc. On lipid metabolism. Chem Pharm Bull (Tokyo). 1982;30:1766–70.
30. Kim YS, Lee YM, Kim H, et al. Anti-obesity effect of Morus bombycina root extract: anti-lipase activity and lipolytic effect. J Ethnopharmacol. 2010;130:621–4.
31. Xie W, Wang W, Su H, Xing D, Cai G, Du L. Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins. J Pharmocol Sci. 2007;103:267–74.
32. Finar IL. Organic chemistry. The Fundamental Principles. 4th ed. Vol 1. New York: Wiley; 1963.
33. Do Nascimento GP, Lemos LT, Bizzera MA, et al. Antibacterial and antioxidant activities of Ursolic acid and derivatives. Molecules. 2014;19:1317–27.
34. Martins D, Carrion LL, Ramos DF, et al. Triptolene and the antimycobacterial activity of Dufraea macrophylla Huber (Rubiacaeae). Biomed Res Int. 2013;2013:605831.
35. Yan XH, Guo YW. Two new ellagic acid glycosides from leaves of Dipsacaceae. J Asian Nat Prod Res. 2004;6:271–6.
36. Kien L, Miron A, Pemp E, Peur U, Kopp B. Flavonoids from Achillea nobilis L. Z Naturfororsch C. 2003;58:11–6.
37. Binuk S, Kaleb A, Raghaven H. Radical scavenging activities of the leaf extracts and a flavonoid glycoside isolated from Cineraria abyssinica Sch. Bipl. Exa. Rich. J App Pharmac Sci. 2012;2:44–9.
38. Moon BH, Lee SC, et al. Complete assignments of the 1H and 13C NMR data of Flavone derivatives. Bull Kor Chem Soc. 2005;26:603–8.
39. Liu J. Pharmacology of oleanolic acid and ursoic acid. J Ethnopharmacol. 1995;49:57–68.
40. Ovesna Z, Kozick S, Slamenova D. Protective effects of ursoic acid and oleanolic acid in leukemic cells. Mutat Res. 2006;600:1103–17.
41. Ramachandran S, Prasad NR. Effect of ursoic acid, a triterpenoid antioxidant, on ultraviolet-B radiation-induced cytotoxicity, lipid peroxidation and DNA damage in human lymphocytes. Chem Biol Interact. 2008;175:99–107.
42. Huang CY, Lin CY, Tsai CW, Yin MC. Inhibition of cell proliferation, invasion and migration by ursoic acid in human lung cancer cell lines. Toxicol in Vitro. 2011;25:1274–80.
43. Somova LO, Nadar A, Rammanan P, Shode FO. Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursoic acids in experimental hypertension. Phytochemistry. 2003;61:11–21.
44. Jana S, Mandlekar S, Marathe P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.Curr Med Chem. 2010;17:3874–908.
45. Prodrug TB. Objectives and design A2 - Taylor, John B. In: Triggle DJ, editor. Comprehensive medicinal chemistry II. Oxford: Elsevier; 2007. p. 1009–41.
46. Li ZG. Synergistic effect of antioxidant system and osmolyte in hydrogen sulfide and salicylic acid cross-talk-induced heat tolerance in maize (Zea mays L) seedlings. Plant Signal Behav. 2015;10:e105–1278.
47. Usta C, Ozdemir S, Schiarti M, Schiarti MF, puddu PE. The pharmacological use of ellagic acid-rich pomegranate fruit. Int J Food Nutr. 2013;64:907–13.
48. Lee YH, Kim HJ, Yoo H, et al. Synthesis of (2’-amino) ethyl derivatives of quercetin 3-O-methyl ether and their antioxidant and neuroprotective effects. Bioorg Med Chem. 2015.
49. Metodiewa D, Kochman AF, Karolczak S. Evidence for antiradical and antioxidant properties of four biologically active N,N-diethylaminoethyl ethers of flavanone oximes: a comparison with natural polyphenolic flavonoids (rutin) action. Biochem Mol Biol Int. 1997:1067–75.
50. Koh GC, Peacock JJ, van der PT, Wiersinga WJ. The impact of diabetes on the pathogenesis of sepsis. Eur J Clin Microbiol Infect Dis. 2012;31:379–88.
51. Pettersson US, Christofferson G, Massena S, et al. Increased recruitment but impaired function of leukocytes during inflammation in mouse models of type 1 and type 2 diabetes. PLoS One. 2011;6:e2480.
52. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16:Suppl 1:S27–36.
53. Knapp S. Diabetes and infection: is there a link? A mini-review. Gerontology. 2013;59:99–104.
54. Wang L, Wang GL, Liu JH, Li D, Zhu DZ, Wu LN. Effects of ursoic acid in ameliorating insulin resistance in liver of KKay mice via peroxisome proliferator-activated receptors alpha and gamma. Zhong Xi Yi Jie He Xue Bao. 2011;30:703–9.
55. He K, Song S, Zou Z, et al. The Hypoglycemic and synergistic effect of Loganin, Morroniside, and Ursoic acid isolated from the fruits of Comus officinalis. Phytother Res. 2016;283–91.
56. Kyriakis E, Stravodimos GA, Kantsadi AL, Chatzileontiadou DS, Skamnaki VT, Angelidou TT, Leonidas DD. Natural flavonoids as antidiabetic agents. The binding of gallic and ellagic acids to glycogen phosphorylase b. FEBS Lett. 2015:178–94.
57. Habtemariam S, Lenti Gi. The therapeutic potential of rutin for diabetes: an update. Mini Rev Med Chem. 2015;15:524–8.
58. Jadhav R, Puchchakayala G. Hypoglycemic and antidiabetic activity of flavonoids: boswellic acid, ellagic acid, quercetin, rutin on streptozotocin-nicotinamide induced type 2 diabetic rats. Int J Pharm Pharm Sci. 2012;4:251–6.
59. Jia Y, Bhuymon MJ, Jun HJ, et al. Ursoic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism. Bioorg Med Chem Lett. 2011;21:5876–80.